USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ACTIVESITE PHARMACEUTICALS, INC.
City: BERKELEY
State: CA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $224,868.00 1
SBIR Phase II $2,184,778.00 2

Award List:

Novel Anti-Thrombotic Approach for Treatment of Myocardial Infarction

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tamie Chilcote
Award Amount: $224,868.00
Abstract:
DESCRIPTION (provided by applicant): More than 850,000 myocardial infarctions (MI) occur in the US annually, 300,000 of which are recurrences, carrying with them a two-fold increased risk of death. Recurrent MI take place owing to the high rates of reocclu sion of cardiac arteries observed following… More

Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Tamie Chilcote
Award Amount: $824,835.00
Abstract:
DESCRIPTION (provided by applicant): There nearly 24 million people in the U.S. who suffer from diabetes and who are at risk for diabetic retinopathy (DR), a vascular complication of diabetes that is the leading cause of blindness in working age adults. A major cause of vision loss in DR is… More

Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Tamie Chilcote – 415-596-7660
Award Amount: $1,359,943.00
Abstract:
DESCRIPTION (provided by applicant): There are nearly 24 million people in the U.S. who suffer from diabetes and all are at risk for developing diabetic macular edema (DME), a vision-threatening retinal complication of diabetes that is the leading cause of blindness in working age adults.… More